Pfizer Confirms U.S. Patent Term Extension for IBRANCE tol March 2027

 Pfizer Inc. (NYSE: PFE) today announced that the U.S. Patent and Trademark Office (USPTO) recently issued a U.S. Patent Term Extension (PTE) certificate for IBRANCE® (palbociclib). The certificate extends the term of U.S. Patent No. RE47,739 (‘739) by more than four years until March 5, 2027. The PTE certificate was granted under the patent restoration provisions of the Drug Price Competition and Patent Term Restoration Act of 1984.

https://www.businesswire.com/news/home/20210205005079/en/Pfizer-Confirms-U.S.-Patent-Term-Extension-for-IBRANCE%C2%AE-palbociclib-Until-March-2027